433 related articles for article (PubMed ID: 15701211)
1. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US.
Crown WH; Bresnahan BW; Orsini LS; Kennedy S; Leonardi C
Curr Med Res Opin; 2004 Dec; 20(12):1929-36. PubMed ID: 15701211
[TBL] [Abstract][Full Text] [Related]
2. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
Feldman SR; Evans C; Russell MW
J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
[TBL] [Abstract][Full Text] [Related]
3. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
4. The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder.
Asche CV; Joish VN; Camacho F; Drake CL
Curr Med Res Opin; 2010 Aug; 26(8):1843-53. PubMed ID: 20515321
[TBL] [Abstract][Full Text] [Related]
5. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain.
Boulanger L; Zhao Y; Foster TS; Fraser K; Bledsoe SL; Russell MW
Curr Med Res Opin; 2009 Jul; 25(7):1763-73. PubMed ID: 19505204
[TBL] [Abstract][Full Text] [Related]
6. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
7. The impact of psoriasis on health care costs and patient work loss.
Fowler JF; Duh MS; Rovba L; Buteau S; Pinheiro L; Lobo F; Sung J; Doyle JJ; Swensen A; Mallett DA; Kosicki G
J Am Acad Dermatol; 2008 Nov; 59(5):772-80. PubMed ID: 19119095
[TBL] [Abstract][Full Text] [Related]
8. Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methods.
Tunceli O; Wade R; Gu T; Bouchard JR; Aagren M; Luo W
Curr Med Res Opin; 2010 Aug; 26(8):1827-34. PubMed ID: 20491613
[TBL] [Abstract][Full Text] [Related]
9. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
10. Estimation of economic costs associated with transfusion dependence in adults with MDS.
Frytak JR; Henk HJ; De Castro CM; Halpern R; Nelson M
Curr Med Res Opin; 2009 Aug; 25(8):1941-51. PubMed ID: 19552620
[TBL] [Abstract][Full Text] [Related]
11. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis.
Gore M; Tai KS; Sadosky A; Leslie D; Stacey BR
J Med Econ; 2011; 14(4):497-507. PubMed ID: 21682606
[TBL] [Abstract][Full Text] [Related]
12. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
13. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002.
Robinson D; Hackett M; Wong J; Kimball AB; Cohen R; Bala M;
Curr Med Res Opin; 2006 May; 22(5):989-1000. PubMed ID: 16709321
[TBL] [Abstract][Full Text] [Related]
14. Cost of care for new versus recurrent acute coronary syndrome patients.
Shetty S; Halpern R; McCollam PL
J Med Econ; 2008; 11(1):81-99. PubMed ID: 19450112
[TBL] [Abstract][Full Text] [Related]
15. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany.
Berger K; Ehlken B; Kugland B; Augustin M
J Dtsch Dermatol Ges; 2005 Jul; 3(7):511-8. PubMed ID: 15967010
[TBL] [Abstract][Full Text] [Related]
16. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study.
Schöffski O; Augustin M; Prinz J; Rauner K; Schubert E; Sohn S; Reich K
J Dtsch Dermatol Ges; 2007 Mar; 5(3):209-18. PubMed ID: 17338796
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic, pharmacy-based, and self-reported health measures in risk equalization models.
Stam PJ; van Vliet RC; van de Ven WP
Med Care; 2010 May; 48(5):448-57. PubMed ID: 20393368
[TBL] [Abstract][Full Text] [Related]
18. Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States.
Ivanova JI; Birnbaum HG; Kidolezi Y; Qiu Y; Mallett D; Caleo S
Epilepsia; 2010 May; 51(5):838-44. PubMed ID: 20002150
[TBL] [Abstract][Full Text] [Related]
19. Economic burden of psoriasis compared to the general population and stratified by disease severity.
Yu AP; Tang J; Xie J; Wu EQ; Gupta SR; Bao Y; Mulani PM
Curr Med Res Opin; 2009 Oct; 25(10):2429-38. PubMed ID: 19663687
[TBL] [Abstract][Full Text] [Related]
20. Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA.
Joyce AT; Smith P; Khandker R; Melin JM; Singh A
J Rheumatol; 2009 Apr; 36(4):743-52. PubMed ID: 19228658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
